Sunitinib tolerance following an initial exposure period: Results of longitudinal PRO data from S-TRAC study
Year: 2018
Type: article
Abstract: Background: Sunitinib (SU) was FDA-approved for adjuvant treatment of patients (pts) with renal cell carcinoma (RCC) at high risk of recurrence post nephrectomy, based upon a 24% reduction in disease-free survival with up to 1 year of SU treatment vs placebo (PBO) (S-TRAC trial). The analysis of patient-reported outcomes (PRO) data showed a statistically significant difference favoring PBO in most EORTC QLQ-C30 scales, and in the symptoms appetite loss and diarrhea, a clinically meaningful difference (≥ 10 points) favoring PBO was observed.
Source: Annals of Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2897707595